Between 1997 and 2001, a single-center chart review demonstrated significant impact of endoscopic ultrasonography in evaluating suspected pancreatic cancer.
Dr Jesse Lachter and colleagues repeated and compared this review with that from 2001 to 2004.
The research team determined whether increased use of endoscopic ultrasonography results in more patients being accurately chosen for curative versus palliative procedures, and for surgical versus nonsurgical oncotherapy.
|47% were preoperatively staged by endoscopic ultrasonography|
The systematic review was made up of electronic files from the gastroenterology, oncology, and pathology departments of patients presenting with suspected pancreatic cancer.
The research team found that from 2001 to 2004, 72 patients had pancreatic cancer.
The team identified 7 tumor types.
The researchers reported that 47% of patients with suspected pancreatic cancer were preoperatively staged by endoscopic ultrasonography.
About 24% of all patients underwent surgery.
Comparatively, from 1997 to 2001, the team observed that only 32% of patients were evaluated by endoscopic ultrasonography, and 45% underwent surgery.
The endoscopic ultrasonography detected a tumor in 32 of 34 cases.
The researchers showed that the endoscopic ultrasonography-guided fine-needle aspiration cytology identified pancreatic cancer in 14 of 18 cases.
F-18-deoxyglucose-positron emission tomography and magnetic resonance imaging were not used.
The team observed that endoscopic retrograde cholangiopancreatography was performed in 29% of patients, with 15 stents inserted.
Dr Lachter's team concluded, "Increased endoscopic ultrasonography use for diagnosing and staging pancreatic cancer resulted in fewer patients undergoing futile surgery."
"The endoscopic ultrasonography plays a pivotal role in the management of patients with pancreatic cancer."